Celebrating Milestones in Netherton NOW Campaign
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has achieved an impressive milestone with its NETHERTON NOW campaign, garnering over one million video views and more than 14 million impressions worldwide. This initiative serves as a beacon of hope and information for patients suffering from Netherton Syndrome, a rare and challenging genetic skin condition.
The Mission Behind NETHERTON NOW
Launched to empower patients, families, and medical experts, the NETHERTON NOW campaign highlights the struggles faced by those affected by Netherton Syndrome. By showcasing personal stories and clinical insights, these videos have found a broad audience across social media and influential platforms like MSN and CBS News, as well as in academic publications.
Voices in the Netherton Community
Denise Carter, Co-Founder and COO of Quoin, expressed the significance of this achievement: "Surpassing one million views reflects the campaign’s progress and the vital voices we’re elevating in the conversation about Netherton Syndrome. We are committed to sharing these stories to help change perceptions and encourage advancements in treatment.”
Advancing Research: QRX003
Quoin's commitment to treating Netherton Syndrome is evident in its lead clinical candidate, QRX003. This promising therapy is undergoing late-stage trials that evaluate its efficacy both as a standalone treatment and in conjunction with existing therapies. Recruitment for participants is currently active across numerous sites, with the goal of completing enrollment by early 2026.
Focus on Clinical Development
As the company moves forward, Dr. Michael Myers, CEO and Co-Founder, emphasizes the importance of delivering effective treatments to address vital healthcare needs. "We remain dedicated to exploring the potential of QRX003 as a groundbreaking treatment for Netherton Syndrome. The encouraging initial results are paving the way for valuable data that will support regulatory approval and, ultimately, the availability of this therapy to patients in need.”
The Importance of Patient-Centered Initiatives
The NETHERTON NOW initiative is just one component of Quoin's ongoing mission. Beyond raising awareness, it seeks to improve education and elevate the voices of those affected by rare diseases. The dedication to community engagement underscores Quoin's approach to addressing the needs of patients and their support networks.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. stands at the forefront of developing treatments for rare and orphan diseases. Their innovative pipeline includes a range of therapies targeting various conditions, demonstrating a strong commitment to meeting unmet medical needs. With a focus on Netherton Syndrome and other rare disorders, Quoin aims to bring transformative solutions to patients and families alike.
Frequently Asked Questions
What is the NETHERTON NOW campaign?
The NETHERTON NOW campaign by Quoin Pharmaceuticals aims to raise awareness and support for patients with Netherton Syndrome, showcasing personal experiences and professional insights.
How many views has the campaign achieved?
The campaign has successfully surpassed one million video views and garnered over 14 million impressions worldwide.
What is QRX003?
QRX003 is Quoin Pharmaceuticals' lead investigational candidate currently undergoing late-stage clinical trials for treating Netherton Syndrome.
When is patient enrollment expected to conclude?
Patient enrollment for the clinical trials is expected to complete in early to mid-Q1 2026.
How can I stay updated on Quoin Pharmaceuticals’ initiatives?
To follow Quoin Pharmaceuticals, visit their official website or follow their social media channels for updates on their programs and initiatives.
